Medications for Metastatic Nonsmall Cell Lung Cancer

12 results

  • braftovi

    (Encorafenib)
    Array BioPharma Inc.
    BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer, all positive for BRAF V600E or V600K mutations. These treatments require combination therapies and FDA-approved testing for mutation detection. Not for wild-type BRAF cancers.

  • keytruda

    (pembrolizumab)
    Merck Sharp & Dohme LLC
    KEYTRUDA® is indicated for various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma, among others. It is utilized in different settings, such as first-line treatment, adjuvant therapy, and for those with advanced or refractory disease.

  • lorbrena

    (lorlatinib)
    Pfizer Laboratories Div Pfizer Inc
    LORBRENA® is indicated for treating adult patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive, confirmed by an FDA-approved test.

  • lumakras

    (sotorasib)
    Amgen Inc
    LUMAKRAS is indicated for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy. It is also indicated in combination with panitumumab for KRAS G12C-mutated metastatic colorectal cancer (mCRC) after specific chemotherapy.

  • mektovi

    (BINIMETINIB)
    Array BioPharma Inc.
    MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.

  • rybrevant

    (Amivantamab)
    Janssen Biotech, Inc.
    RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, both as a first-line treatment and for those previously treated, in combination with approved therapies or as a single agent.

  • tabrecta

    (capmatinib)
    Novartis Pharmaceuticals Corporation
    TABRECTA is indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) characterized by a mutation causing MET exon 14 skipping, as determined by an FDA-approved test.

  • tecentriq

    (atezolizumab)
    Genentech, Inc.
    TECENTRIQ is indicated for various cancers: as adjuvant treatment and first-line therapy for non-small cell lung cancer (NSCLC); for extensive-stage small cell lung cancer (ES-SCLC); for unresectable or metastatic hepatocellular carcinoma (HCC); and for melanoma with BRAF V600 mutation. It also treats unresectable alveolar soft part sarcoma.

  • tepmetko

    (Tepotinib Hydrochloride)
    EMD Serono, Inc.
    TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that has mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

  • vizimpro

    (dacomitinib)
    Pfizer Laboratories Div Pfizer Inc
    VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations, as identified by an FDA-approved test.